期刊文献+

西达本胺对胃癌SGC-7901细胞增殖、凋亡及Notch1、Sirt1基因表达的影响研究 被引量:1

Influence of chidamide on proliferation,apoptosis with expression of Notch1 and Sirt1 in gastric carcinoma cell line SGC-7901
下载PDF
导出
摘要 目的:通过研究组蛋白去乙酰化酶抑制剂西达本胺对Notch1、Sirt1基因表达的影响来探讨其对胃癌细胞株SGC-7901的体外抗增殖作用。方法:采用MTT法观察不同浓度西达本胺对SGC-7901细胞增殖抑制作用,流式细胞仪(FCM)检测细胞凋亡率,RT-PCR检测Sirt1基因表达情况,蛋白质印迹法检测Notch1蛋白表达情况。结果:西达本胺在体外可抑制胃癌细胞SGC-7901增殖,呈浓度、时间依赖性;其可促进细胞凋亡,减少Sirt1基因的表达,下调Notch1蛋白的表达。结论:西达本胺可通过抑制Sirt1基因表达、下调Notch1蛋白的表达来抑制细胞增殖、促进细胞凋亡而发挥体外抗胃癌作用。 Objective: To investigate the influence of chidamide, a histone deacetylase inhibitor(HDACi), on the proliferation inhibition and apoptosis effects to the human gastric carcinoma cell lines SGC-7901 and to explore the related mechanism of Notchl, Sirtl. Methods: SGC-7901 cells were incubated with chidamide at various concentrations and times. Cell growth inhibition was assessed by MTY. Cell apoptosis was analyzed by flow cytomerty(FCM). The expression of Sirtl mRNA were determined by RT-PCR, the protein levels of Notchl were determined by Western blotting. Results: The proliferation of SGC-7901 cell was significantly inhibited and the apoptosis of SGC-7901 cell was promoted by chidamide(P 〈0.05). The expression of Sirtl mRNA and the protein levels of Notchl were reduced by chidamide. Conclusion: Chidamide can promote apoptosis and inhibit proliferation by down-regulation of Sirtl and Notchl expression in gastric carcinoma cells.
出处 《东南大学学报(医学版)》 CAS 2012年第3期273-276,共4页 Journal of Southeast University(Medical Science Edition)
基金 国家自然科学基金面上项目(81172619) 教育部重点实验室开放课题(2011EME010)
关键词 胃癌 西达本胺 组蛋白去乙酰化酶 SIRT1 NOTCH1 基因表达 gastric carcinoma chidamide histone deacetylase Sirtl Notchl gene expression
  • 相关文献

参考文献2

二级参考文献31

  • 1JEMAL A,SIEGEL R,XU J,et al.Cancer statistics[J].Cancer J Clin,2010,60:277-300.
  • 2JEANNET R,MASTIO J,MACIAS-GARCIA A,et al.Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL[J].Blood,2010,116:5443-5454.
  • 3GRAMANTIERI L,GIOVANNINIL C,LANZI A,et al.Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma[J].Liver Int,2009,29:1478-3223.
  • 4QI R,AN ZH,YU Y,et al.Notch1 signaling inhibits growth of human hepatocellular Carcinoma through induction of cell cycle arrest and apoptosis[J].Cancer Res,2003,63:8323-8329.
  • 5MITTAL S,SUBRAMANYAM D,DEY D,et al.Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis[J].Molecular Cancer,2009,8:128.
  • 6RONCHINI C,CAPOBIANCO A J.Induction of cyclin d1 transcription and cdk2 activity by notch(ic):Implication for cell cycle disruption in transformation by notch(ic)[J].Mol Cell Biol,2001,21:5925-5934.
  • 7JUNDT F.Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma[J].Blood,2002,99:3398-3403.
  • 8CARLESSO N,ASTER J C,SKLAR J,et al.Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics[J].Blood,1999,93:838-848.
  • 9RAO S S,O'NEIL J,LIBERATOR C D,et al.Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-Cell acute lymphoblastic leukemia cells[J].Cancer Res,2009,69:3060-308.
  • 10de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378.

共引文献18

同被引文献18

  • 1尹子卉,吴仲闻,兰玉坤,廖晨钟,山松,李志良,宁志强,鲁先平,李志斌.新型抗肿瘤组蛋白去乙酰化酶抑制剂西达本胺的合成[J].中国新药杂志,2004,13(6):536-538. 被引量:8
  • 2HU Z , FAN C, OH D S, et al. The molecular portraits of breast tumors are conserved across microarray platforms[J]. BMC Genomics ,2006 , ( 7) : 96.
  • 3BERTUCCI F,FINETTI P,CERVERA N,et al. How basal are triple- negative breast cancers?[J]. IntJ Cancer, 2008 , 123 (1) :236-240.
  • 4WILLIAMJ , IRVINJr, LISA A. What is triple- negative breast cancer?[J]. EurJ Cancer, 2008 ,44 ( 18) : 2799 - 2805 .
  • 5DIALLO- DANE BROCK R, TING E, GLUZ 0, et al. Prognostic and predictive impact of protein expression profiling in high-risk breast cancer patients treated with high- dose or conven-tional dose- dense chemotherapy[J]. Clin Cancer Res, 2007 , 13 (2) :488-497.
  • 6CAREY LA, PEROU C M, LlV ASY C A, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study[J].JAMA ,2006 ,295 (21) :2492-2502.
  • 7DIALLO- DANEBROCK R, TING E, GLUZ 0, et al. Prognostic and predictive impact of protein expression profiling in high- risk breast cancer patients treated with high- dose or conven-tional dose- dense chemotherapy[J] . Clin Cancer Res, 2007 , 13(2) :488-497.
  • 8BAUER K R,BROWN M,CRESS R D,et al. Descriptive anal-ysis of estrogen receptor ( ER) - negative, progesterone receptor ( PR) - negative, and HER2 - negative invasive breast cancer, the so- called triple- negative phenotype: a population- based study from the California Cancer Registry[J]. Cance, 2007 , 109(9) :1721-1728.
  • 9MINUCCI S, PELICEI P G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer[J]. Nat Rev Cancer ,2006,6(1) :38-51.
  • 10NING Z Q, LI Z B, NEWMAN MJ , et al. Chidamide( CS055/ HBI- 8000) : a new histone deacetylase inhibitor of yhe benzamide class with antitumor activity and the ability to en-hance immune cell- mediated humor cell cytotoxicity[J]. Cancer Chemother Pharmacol, 20 12 ,69 ( 4 ) : 90 1 - 909.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部